• Sat. Jun 3rd, 2023

PreveCeutical Signs Intercompany Sol-Gel License Agreement


Jan 9, 2023
Vancouver, British Columbia–(Newsfile Corp. – January 9, 2023) – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the “Subsidiary” or “PAPL”) for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of cannabinoids (“Sol-Gel License”).PAPL has an exclusive license agreement with UniQue

Read More